NCT04516096 - A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 22, 2020

Primary Completion Date

December 30, 2022

Study Completion Date

January 31, 2023

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

AMX0035

Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day

Trial Locations (5)

Wake Forest Baptist Medical Center, Winston-Salem

University of Michigan Medical Center, Ann Arbor

Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco

Massachusetts General Hospital, Boston

University of Massachusetts Memorial Medical Center, Worcester